Patients at risk of recurrence: emerging concerns regarding a reform of long-term conditions

As the French healthcare system faces an increasing financial imbalance, a major reform concerning long-term illnesses (LTI) raises serious concerns. In 2025, the Health Insurance proposes to review the status of patients suffering from chronic conditions, notably through suspending the LTI scheme for those considered in remission or cured. This measure, envisaged to alleviate a deficit estimated at 16 billion euros this year, but projected to reach 41 billion by 2035, highlights a major issue: how to ensure optimal care without excluding patients at risk of relapse? Faced with the possibility of early exit from the fully reimbursed scheme, the medical community expresses skepticism, recalling the complexity of chronic diseases and often prolonged consequences, including disabling sequelae. Additionally, the reform also plans to create a new “chronic risk” status, with appropriate and graduated coverage. In this environment, pharmaceutical laboratories such as Sanofi, Roche, or Novartis remain key players in research and treatment, operating in a rapidly changing landscape.

The debate is further enriched by questions about the very definition of “complete remission” and the need for continuity of care, especially psychological, for post-treatment patients. This questioning is particularly relevant in illnesses with a high risk of relapse, such as cancers, where patients may have heavy sequelae and persistent anxiety about the possibility of recurrence. The measure, which is only beginning to take shape, could permanently alter the management of LTIs in France, raising calls for vigilance and adaptation of support mechanisms.

Financial and Structural Challenges of the Long-Term Illness Reform

The proposed reform of the Health Insurance highlights a significant economic challenge. Currently, long-term illnesses represent nearly 20% of the French population, about 13.7 million people, but already account for two-thirds of the annual expenses of the Primary Health Insurance Fund (CPAM). This economic burden is criticized as the overall deficit of the Health Insurance exceeds 16 billion euros for the current year, with projections indicating a widening gap potentially reaching 41 billion euros by 2035, posing a significant risk of budget overruns if no corrective measures are taken.

The government project, notably supported by Yannick Neuder, Minister of Health, involves suspending the LTI status for patients considered in complete remission, in order to reduce the full coverage of care within this framework. This suspension would result in a tiered reimbursement system, no longer guaranteeing 100% coverage of medical expenses related to the pathology once the acute phase has passed. The goal set by the Health Insurance is thus to control expenses while trying to avoid systematically excluding patients in case of relapse or late complications.

Another important aspect of the reform aims to defer entry into the LTI scheme by introducing an intermediate status called “chronic risk.” This measure would aim to lighten initial coverage for individuals with a condition requiring monitoring but not immediately warranting full reimbursement, while ensuring access to a specific list of care that is enforceable and reimbursed at 100% for each long-term condition.

• 🌐 A major economic issue: growing deficit and impact on CPAM
• 📉 Targeted reduction of coverage for patients in remission or cured
• ⏳ Delaying the activation of the LTI scheme through a new specific status
• ⚠️ Maintaining access to the scheme in case of relapse or complications

Indicator 📊	Current value	Projection 2035
HealthInsurance deficit	16 billion €	41 billion €
LTI population	13.7 million (20% of the population)	Estimated increase
Share of CPAM expenses dedicated to LTIs	2/3	3/4

Impact on Care: What Would Change if the LTI Status Ends in Remission

Currently, the LTI status guarantees 100% reimbursement by Social Security for care related to severe or chronic conditions. This full coverage, renewed every five years, provides patients with substantial financial support, especially important for serious illnesses like cancer, diabetes, or Alzheimer’s disease. The proposal to remove the LTI status as soon as the patient is considered in complete remission disrupts this traditional mechanism.

In this scenario, the patient would no longer automatically benefit from 100% coverage for their condition, exposing them to additional costs, particularly in areas where fee overruns are common—an issue already highlighted by many practitioners. The scheme does, in theory, allow re-entry into the LTI program in case of relapse or late-onset sequelae, but the speed and simplicity of this re-integration are debated.

Furthermore, suspending the LTI status would affect patients whose medical follow-up remains essential, notably in oncology, where hormone treatments or prolonged monitoring are integral parts of the care pathway. A concrete example: for breast cancer, hormone therapy can last at least five years, underscoring the arbitrariness surrounding the notion of “complete remission.”

• 💊 Reduced access to 100% reimbursements related to care
• 💸 Increased risk of patient-incurred costs (overruns, deductibles)
• 📅 Need for diligent medical follow-up, even during remission
• 🔄 Possibility of returning to the LTI scheme in case of relapse, but ongoing uncertainties

Aspects Covered	Current LTI situation	Post-reform (in remission)
Medical care reimbursement	100% Social Security	Variable, probably partial
Post-treatment follow-up	Ease and full support	Several consultations might be considered outside the LTI scheme
Medication coverage	Full coverage depending on condition	Risk of differentiated coverage
Psychological support	Recommended and accessible	Less protected, criticized by professionals

This reform, which aims to ease the financial pressure on the system, raises strong concerns about the risks of premature exit from the scheme, particularly due to psychological and anxious issues related to fear of relapse. The Gustave-Roussy center highlights that nearly 63.5% of cancer survivors continue to experience severe sequelae affecting their quality of life in the long term, raising questions about the relevance of suspending the LTI status under these conditions (source).

Medical Perspectives: Between Caution and Skepticism

In response to the reform proposals, practitioners and specialists in chronic conditions advocate for increased vigilance. They emphasize that even under the LTI status, patients often still face additional costs not covered, such as fee overruns or certain deductibles. Removing the scheme in case of “remission” would amplify these financial difficulties for patients whose health remains fragile.

For example, Catherine Simonin, representative of the Ligue contre le cancer, tempers the idea: “In some cases, such as after surgery without additional treatment, suspending the LTI might be considered. But it remains very situation-dependent.”

Meanwhile, Professor Olivier Cussenot of the National Prostate Cancer Patients’ Association recalls that the definition of “complete remission” remains a theoretical and arbitrary concept. Indeed, some patients can relapse after several decades. This uncertainty leads specialists to criticize a too strict timetable for suspending the LTI status.

• 👨‍⚕️ Risk of worsening inequalities in access to care
• ⚠️ Difficulty in defining remission precisely as the sole criterion
• 🕰 Importance of sustained medical and psychological follow-up
• 🔎 Call for a more nuanced gradation rather than a sharp cutoff

Medical Arguments	Details
Fee overruns	Still present under LTI, likely to increase
Possible relapse after 20 years	Example: prostate cancer
Heavy sequelae post-cancer	63.5% of patients retain sequelae
Necessary psychological follow-up	Crucial for anxious patients

The Risks of Premature Exit from the LTI Scheme for Patients at Risk of Recurrence

An early exit from the LTI scheme raises several medical but also social risks. For illnesses characterized by a strong tendency to relapse or complications, abrupt discontinuation of comprehensive care can lead to interruptions in the treatment pathway. These disruptions are likely to cause health deteriorations, more frequent use of emergency services, or even a general decline in quality of life.

Post-cancer disorders, both physical and psychological, exemplify these issues. The persistent fear of recurrence, combined with chronic pain or functional disorders, makes ongoing follow-up and support essential. However, the new scheme could limit this continuity.

• ⚕️ Increased risk of untreated complications
• 🔄 Difficulties re-integrating into the scheme in case of relapse
• 🧠 Disruption of psychological support
• 🏥 Risk of increased hospital service use

Possible consequences	Impacts
Break in medical follow-up	Possible health deterioration
Loss of 100% coverage	Increased financial burden
Increased anxiety	Impediment to regular psychological support
Increased hospital visits	Additional costs for Health Insurance

Experts emphasize the need to anticipate these risks and implement a dynamic and personalized follow-up capable of adapting to the patient’s evolution. This approach closely resembles proven models such as the R-B-R (Risk-Need-Receptivity) model, used in some international prevention schemes to target the most vulnerable patients (source).

The Role of Pharmaceutical Labs in the Evolution of Chronic Disease Treatment

In a context of reform and budget tensions, major pharmaceutical laboratories are key players, including Sanofi, Servier, Ipsen, Roche, Bayer, Novartis, Amgen, Merck, GSK, and Pfizer. Their role goes beyond supplying medications; it extends to innovative patient support, the development of targeted therapies, and collaboration with health authorities to optimize care.

Recent pharmaceutical advances in the treatment of cancer, cardiovascular diseases, and diabetes fit within this dynamic. For example, hormone therapy for breast cancer, supported by laboratories like Novartis or Roche, illustrates the importance of extended monitoring, which cannot be compromised by early suspension of the LTI scheme.

• 🔬 Research and therapeutic innovation for chronic diseases
• 🤝 Collaboration with public health actors
• 🌍 Development of personalized care protocols
• 💊 Long-term treatments essential for remission

Laboratory 🏢	Intervention areas	Examples of treatments
Sanofi	Diabetes, cardiovascular diseases	Insulin injections, monoclonal antibodies
Roche	Oncology, hematology	Hormone therapy, immunotherapies
Novartis	Cancer, autoimmune diseases	Targeted therapies, oral treatments
Pfizer	Oncology, inflammation	Tyrosine kinase inhibitors

Perspectives on Support Mechanisms and Psychological Care

Another crucial aspect concerns the psychological follow-up of LTI patients, especially those at high risk of relapse, such as post-cancer patients. The fear of recurrence, often underestimated, causes chronic stress and anxious vigilance, which require tailored and often extended care.

The reform presents a major risk of undermining this psychological support by reducing automatic recognition of 100% coverage. Yet, testimonials from professionals like René Ducroux, president of Atoutcancer, recall that this support is essential to maintain quality of life and prevent severe psychological decompensations.

• 🧠 Importance of regular psychological follow-up
• 👥 Prevention of anxiety related to recurrence fears
• 🔄 Need for integrated care between somatic and psychological treatments
• 📈 Risk of overall health decline without support

Care Element	Current situation	Post-reform risk
Access to psychological follow-up	Encouraged and often covered	Less systematic, risk of rupture
Support for quality of life	Maintained through LTI mechanisms	Increased fragility
Post-therapy follow-up	Continuous and individualized	Possible interruption
Prevention of psychological relapses	Priority	Less well ensured

International Comparison: Strategies and Management of Long-Term Conditions

The issue of long-term illnesses and relapse risk is not unique to France. Several European countries have experimented with various approaches to balance healthcare spending control and quality of chronic patient follow-up. In Germany, for example, implementing a hierarchical care system with tailored reimbursement levels aims to manage these complex situations.

In the UK, the National Health Service (NHS) favors integrated follow-up across hospital and primary care sectors, with enhanced support for patients at high risk of relapse. These measures combine robust funding and close care coordination, while seeking to prevent disruptions.

• 🇩🇪 Germany: gradual adaptation of care levels
• 🇬🇧 UK: integrated follow-up and care coordination
• 🇫🇷 France: partial suspension project, still under debate
• 🌐 Potential learning from foreign models

Countries 🌍	Main approach	Advantages	Disadvantages
Germany	Gradual reimbursement levels	Cost control, flexibility	Administrative complexity
United Kingdom	Multidisciplinary integrated follow-up	Continuity of care, prevention	System resource strain
France (project)	Partial suspension of the LTI status	Potential cost reduction	Risk of excluding vulnerable patients

FAQ – Frequently Asked Questions about the Long-Term Illness Reform and Relapse Risks

• ❓ What exactly is the LTI status?
  The LTI status allows for full coverage by Social Security of care related to a chronic or severe condition requiring prolonged treatment.
• ❓ Why does the Health Insurance want to reform this scheme?
  Facing a growing deficit, the Health Insurance seeks to control expenses by suspending the scheme for patients in complete remission, while maintaining options for re-entry.
• ❓ What are the risks of prematurely exiting the LTI scheme?
  Early exit can cause interruptions in medical follow-up, increased costs for patients, and significant psychological fragility.
• ❓ How do pharmaceutical labs contribute to this evolution?
  They develop innovative treatments, extend therapeutic possibilities, and collaborate with authorities to optimize the management of long-term conditions.
• ❓ Are there alternatives and foreign models to manage these issues?
  Countries such as Germany and the UK have implemented graduated or integrated systems that could serve as references to refine the French reform.

Source: www.letelegramme.fr